Human Ebola Virus Species and Compositions and Methods Thereof

• US 20120251502A1
• Filed: 10/26/2009
• Published: 10/04/2012
• Est. Priority Date: 10/24/2008
• Status: Abandoned Application

• Current Assignee: United States Department Of Health And Human Services (Government of the United States of America)
• Original Assignee: Government of The US As Represented By The Secretary of The Dept of Health and Human Services
• Inventors: Nichol, Stuart T., Towner, Jonathan S., Comer, James A., Ksiazek, Thomas G., Rollin, Pierre E.
• Application Number:
  US13/125,890
• Publication Number:
  US 20120251502A1
• Time in Patent Office: Days
• US Class Current: 424/93.6
• CPC Class Codes: A61K 2039/5254 avirulent or attenuated
• CPC Class Codes: A61K 2039/5256 expressing foreign proteins
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/542 oral/gastrointestinal
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/10 from RNA viruses
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
• CPC Class Codes: C12N 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 2760/14143 viral genome or elements thereof as genetic vector
• CPC Class Codes: C12N 2760/14145 Special targeting system for viral vectors
• CPC Class Codes: C12N 2810/6072 negative strand RNA viruses
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12Q 1/701 Specific hybridization probes
• CPC Class Codes: G01N 2333/08 RNA viruses
• CPC Class Codes: G01N 33/56983 Viruses

Abstract

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

Claims

1. An isolated hEbola virus comprising a nucleic acid molecule comprising a nucleotide sequence of:

a) a nucleotide sequence set forth in SEQ ID NOS;

1 or 10;

b) a nucleotide sequence hybridizing under stringent conditions to SEQ ID NOS;

1 or 10;

or

c) a nucleotide sequence of at least 70%-99% identity to the SEQ ID NOS;

1 or 10, with the proviso that said nucleotide sequence is not SEQ ID NO;

20.

3. The hEbola virus of claim 1 which is killed.

4. The hEbola virus of claim 1 which is an attenuated hEbola virus.

5. The virus of claim 4 wherein at least one property of the attenuated hEbola virus is reduced from among infectivity, replication ability, protein synthesis ability, assembling ability or cytopathic effect.

20. The hEbola virus of claims 3 or 4, or a protein extract therefrom, and a pharmaceutically acceptable carrier.

2. An isolated hEbola virus having Centers for Disease Control Deposit Accession No. 200706291.

6. An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NOS:

1 or 10 or a complement thereof, or a fragment thereof wherein said fragment comprises a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS;

1 or 10, or a complement thereof;

with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO;

20;

or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS;

1 or 10, or a complement thereof.

7. The isolated nucleic acid molecule of claim 6 comprising a nucleotide sequence of between 4 and 4900 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS:

1 or 10, or a complement thereof;

with the proviso that said nucleotide sequence is not comprised by the nucleotide sequence set forth in SEQ ID NO;

20;

or between 5500 and 6600 contiguous nucleotides of the nucleotide sequence of SEQ ID NOS;

1 or 10, or a complement thereof.

8. The isolated nucleic acid molecule of claim 7 comprising a nucleotide sequence that encodes the amino acid sequence of SEQ ID NO:

2-9, 59, or SEQ ID NO;

11-19 or a complement thereof.

10. An isolated polypeptide encoded by the nucleic acid molecule of claim 7.

11. The polypeptide of claim 10 comprising the amino acid of:

a) an amino acid sequence set forth in any of SEQ ID NOS;

2-19, or 59;

or

b) an amino acid sequence that has 70%-99% homology to the amino acid sequence of (a).

12. The polypeptide of claim 10 wherein the amino acid sequence has

5 to 250 contiguous amino acid residues of the amino acid sequence of SEQ ID NOS:

5 or 18 (VP24);

5 to 280 contiguous residues of the amino acid sequence of SEQ ID NOS;

6 or 17 (VP30);

5 to 320 contiguous residues of the amino acid sequence of SEQ ID NOS;

8 or 13 (VP40);

5 to 340 contiguous residues of the amino acid sequence of SEQ ID NOS;

7 or 12 (VP35);

5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS;

4 or 15 (SGP);

5 to 370 contiguous residues of the amino acid sequence of SEQ ID NOS;

59 or 16 (SSGP);

5 to 670 contiguous residues of the amino acid sequence of SEQ ID NOS;

9 or 14 (GP);

5 to 730 contiguous residues of the amino acid sequence of SEQ ID NOS;

3 or 11 (NP);

or

5 to 2200 contiguous residues of the amino acid sequence of SEQ ID NOS;

2 or 19 (L).

22. The nucleic acid molecule of claims 6 or 9, and a pharmaceutically acceptable carrier.

9. An isolated RNA or DNA nucleic acid molecule which hybridizes under stringent conditions to a nucleic acid molecule having the nucleotide sequence of SEQ ID NOS:

1 or 10 or a complement thereof.

13. (canceled)

14. (canceled)

15. (canceled)

16. (canceled)

17. (canceled)

18. (canceled)

19. (canceled)

21. (canceled)

23. (canceled)

24. (canceled)

25. (canceled)

26. (canceled)

27. (canceled)

28. (canceled)

29. (canceled)

30. (canceled)